MedTrace Logo

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

NCT05733611 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-02

No results posted yet for this study

Summary

This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.

Conditions

  • Refractory Metastatic Colorectal Cancer
  • pMMR
  • MSS

Interventions

BIOLOGICAL

RP2

Genetically modified herpes simplex type 1 virus

BIOLOGICAL

RP3

Genetically modified herpes simplex type 1 virus

BIOLOGICAL

atezolizumab

anti-PD-L1 monoclonal antibody

BIOLOGICAL

bevacizumab

anti-VEGF therapy

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Replimune Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Vanasse, MD · Replimune Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2025-08-18
Completion
2025-08-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733611 on ClinicalTrials.gov